カテゴリー： 世界, 医療/バイオ, Market Monitor Global

世界の尿路感染症（UTI）治療薬市場予測2023-2029：ジェネリック医薬品、先発医薬品

【英語タイトル】Urinary Tract Infection (UTI) Medications Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料（MMG23FB2229）・商品コード：MMG23FB2229
・発行会社（調査会社）：Market Monitor Global
・発行日：2023年2月
・ページ数：62
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の尿路感染症（UTI）治療薬市場規模と予測を収録しています。・世界の尿路感染症（UTI）治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の尿路感染症（UTI）治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の尿路感染症（UTI）治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ジェネリック医薬品」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

尿路感染症（UTI）治療薬のグローバル主要企業は、Pfizer、AstraZeneca、Novartis International、Johnson & Johnson、Roche Holding AG、Teva Pharmaceutical lndustries、Boehringer Ingelheim、Cipla、AdvaCare Pharma、Baiyunshan Pharma、Harbin Pharmaceutical Group、Aurobindo Pharma、Alkem Laboratories、Ascend Laboratoriesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、尿路感染症（UTI）治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の尿路感染症（UTI）治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の尿路感染症（UTI）治療薬市場：タイプ別市場シェア、2022年
・ジェネリック医薬品、先発医薬品

世界の尿路感染症（UTI）治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の尿路感染症（UTI）治療薬市場：用途別市場シェア、2022年
・病院薬局、小売薬局、Eコマース

世界の尿路感染症（UTI）治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の尿路感染症（UTI）治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における尿路感染症（UTI）治療薬のグローバル売上、2018年-2023年
・主要企業における尿路感染症（UTI）治療薬のグローバル売上シェア、2022年
・主要企業における尿路感染症（UTI）治療薬のグローバル販売量、2018年-2023年
・主要企業における尿路感染症（UTI）治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Pfizer、AstraZeneca、Novartis International、Johnson & Johnson、Roche Holding AG、Teva Pharmaceutical lndustries、Boehringer Ingelheim、Cipla、AdvaCare Pharma、Baiyunshan Pharma、Harbin Pharmaceutical Group、Aurobindo Pharma、Alkem Laboratories、Ascend Laboratories

*************************************************************

・調査・分析レポートの概要
尿路感染症（UTI）治療薬市場の定義
市場セグメント
世界の尿路感染症（UTI）治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の尿路感染症（UTI）治療薬市場規模
世界の尿路感染症（UTI）治療薬市場規模：2022年 VS 2029年
世界の尿路感染症（UTI）治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの尿路感染症（UTI）治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の尿路感染症（UTI）治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：ジェネリック医薬品、先発医薬品
尿路感染症（UTI）治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院薬局、小売薬局、Eコマース
尿路感染症（UTI）治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別尿路感染症（UTI）治療薬市場規模 2022年と2029年
地域別尿路感染症（UTI）治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Pfizer、AstraZeneca、Novartis International、Johnson & Johnson、Roche Holding AG、Teva Pharmaceutical lndustries、Boehringer Ingelheim、Cipla、AdvaCare Pharma、Baiyunshan Pharma、Harbin Pharmaceutical Group、Aurobindo Pharma、Alkem Laboratories、Ascend Laboratories
…

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Urinary Tract Infection (UTI) Medications Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Urinary Tract Infection (UTI) Medications Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Urinary Tract Infection (UTI) Medications Overall Market Size
2.1 Global Urinary Tract Infection (UTI) Medications Market Size: 2022 VS 2029
2.2 Global Urinary Tract Infection (UTI) Medications Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Urinary Tract Infection (UTI) Medications Players in Global Market
3.2 Top Global Urinary Tract Infection (UTI) Medications Companies Ranked by Revenue
3.3 Global Urinary Tract Infection (UTI) Medications Revenue by Companies
3.4 Top 3 and Top 5 Urinary Tract Infection (UTI) Medications Companies in Global Market, by Revenue in 2022
3.5 Global Companies Urinary Tract Infection (UTI) Medications Product Type
3.6 Tier 1, Tier 2 and Tier 3 Urinary Tract Infection (UTI) Medications Players in Global Market
3.6.1 List of Global Tier 1 Urinary Tract Infection (UTI) Medications Companies
3.6.2 List of Global Tier 2 and Tier 3 Urinary Tract Infection (UTI) Medications Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Urinary Tract Infection (UTI) Medications Market Size Markets, 2022 & 2029
4.1.2 Generic Drugs
4.1.3 Original Drug
4.2 By Type – Global Urinary Tract Infection (UTI) Medications Revenue & Forecasts
4.2.1 By Type – Global Urinary Tract Infection (UTI) Medications Revenue, 2018-2023
4.2.2 By Type – Global Urinary Tract Infection (UTI) Medications Revenue, 2024-2029
4.2.3 By Type – Global Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Urinary Tract Infection (UTI) Medications Market Size, 2022 & 2029
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 E-Commerce
5.2 By Application – Global Urinary Tract Infection (UTI) Medications Revenue & Forecasts
5.2.1 By Application – Global Urinary Tract Infection (UTI) Medications Revenue, 2018-2023
5.2.2 By Application – Global Urinary Tract Infection (UTI) Medications Revenue, 2024-2029
5.2.3 By Application – Global Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Urinary Tract Infection (UTI) Medications Market Size, 2022 & 2029
6.2 By Region – Global Urinary Tract Infection (UTI) Medications Revenue & Forecasts
6.2.1 By Region – Global Urinary Tract Infection (UTI) Medications Revenue, 2018-2023
6.2.2 By Region – Global Urinary Tract Infection (UTI) Medications Revenue, 2024-2029
6.2.3 By Region – Global Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Urinary Tract Infection (UTI) Medications Revenue, 2018-2029
6.3.2 US Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.3.3 Canada Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.3.4 Mexico Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Urinary Tract Infection (UTI) Medications Revenue, 2018-2029
6.4.2 Germany Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.4.3 France Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.4.4 U.K. Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.4.5 Italy Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.4.6 Russia Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.4.7 Nordic Countries Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.4.8 Benelux Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Urinary Tract Infection (UTI) Medications Revenue, 2018-2029
6.5.2 China Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.5.3 Japan Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.5.4 South Korea Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.5.5 Southeast Asia Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.5.6 India Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Urinary Tract Infection (UTI) Medications Revenue, 2018-2029
6.6.2 Brazil Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.6.3 Argentina Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Urinary Tract Infection (UTI) Medications Revenue, 2018-2029
6.7.2 Turkey Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.7.3 Israel Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.7.4 Saudi Arabia Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.7.5 UAE Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
7 Urinary Tract Infection (UTI) Medications Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Urinary Tract Infection (UTI) Medications Major Product Offerings
7.1.4 Pfizer Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 AstraZeneca
7.2.1 AstraZeneca Company Summary
7.2.2 AstraZeneca Business Overview
7.2.3 AstraZeneca Urinary Tract Infection (UTI) Medications Major Product Offerings
7.2.4 AstraZeneca Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.2.5 AstraZeneca Key News & Latest Developments
7.3 Novartis International
7.3.1 Novartis International Company Summary
7.3.2 Novartis International Business Overview
7.3.3 Novartis International Urinary Tract Infection (UTI) Medications Major Product Offerings
7.3.4 Novartis International Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.3.5 Novartis International Key News & Latest Developments
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Company Summary
7.4.2 Johnson & Johnson Business Overview
7.4.3 Johnson & Johnson Urinary Tract Infection (UTI) Medications Major Product Offerings
7.4.4 Johnson & Johnson Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.4.5 Johnson & Johnson Key News & Latest Developments
7.5 Roche Holding AG
7.5.1 Roche Holding AG Company Summary
7.5.2 Roche Holding AG Business Overview
7.5.3 Roche Holding AG Urinary Tract Infection (UTI) Medications Major Product Offerings
7.5.4 Roche Holding AG Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.5.5 Roche Holding AG Key News & Latest Developments
7.6 Teva Pharmaceutical lndustries
7.6.1 Teva Pharmaceutical lndustries Company Summary
7.6.2 Teva Pharmaceutical lndustries Business Overview
7.6.3 Teva Pharmaceutical lndustries Urinary Tract Infection (UTI) Medications Major Product Offerings
7.6.4 Teva Pharmaceutical lndustries Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.6.5 Teva Pharmaceutical lndustries Key News & Latest Developments
7.7 Boehringer Ingelheim
7.7.1 Boehringer Ingelheim Company Summary
7.7.2 Boehringer Ingelheim Business Overview
7.7.3 Boehringer Ingelheim Urinary Tract Infection (UTI) Medications Major Product Offerings
7.7.4 Boehringer Ingelheim Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.7.5 Boehringer Ingelheim Key News & Latest Developments
7.8 Cipla
7.8.1 Cipla Company Summary
7.8.2 Cipla Business Overview
7.8.3 Cipla Urinary Tract Infection (UTI) Medications Major Product Offerings
7.8.4 Cipla Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.8.5 Cipla Key News & Latest Developments
7.9 AdvaCare Pharma
7.9.1 AdvaCare Pharma Company Summary
7.9.2 AdvaCare Pharma Business Overview
7.9.3 AdvaCare Pharma Urinary Tract Infection (UTI) Medications Major Product Offerings
7.9.4 AdvaCare Pharma Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.9.5 AdvaCare Pharma Key News & Latest Developments
7.10 Baiyunshan Pharma
7.10.1 Baiyunshan Pharma Company Summary
7.10.2 Baiyunshan Pharma Business Overview
7.10.3 Baiyunshan Pharma Urinary Tract Infection (UTI) Medications Major Product Offerings
7.10.4 Baiyunshan Pharma Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.10.5 Baiyunshan Pharma Key News & Latest Developments
7.11 Harbin Pharmaceutical Group
7.11.1 Harbin Pharmaceutical Group Company Summary
7.11.2 Harbin Pharmaceutical Group Business Overview
7.11.3 Harbin Pharmaceutical Group Urinary Tract Infection (UTI) Medications Major Product Offerings
7.11.4 Harbin Pharmaceutical Group Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.11.5 Harbin Pharmaceutical Group Key News & Latest Developments
7.12 Aurobindo Pharma
7.12.1 Aurobindo Pharma Company Summary
7.12.2 Aurobindo Pharma Business Overview
7.12.3 Aurobindo Pharma Urinary Tract Infection (UTI) Medications Major Product Offerings
7.12.4 Aurobindo Pharma Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.12.5 Aurobindo Pharma Key News & Latest Developments
7.13 Alkem Laboratories
7.13.1 Alkem Laboratories Company Summary
7.13.2 Alkem Laboratories Business Overview
7.13.3 Alkem Laboratories Urinary Tract Infection (UTI) Medications Major Product Offerings
7.13.4 Alkem Laboratories Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.13.5 Alkem Laboratories Key News & Latest Developments
7.14 Ascend Laboratories
7.14.1 Ascend Laboratories Company Summary
7.14.2 Ascend Laboratories Business Overview
7.14.3 Ascend Laboratories Urinary Tract Infection (UTI) Medications Major Product Offerings
7.14.4 Ascend Laboratories Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.14.5 Ascend Laboratories Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Urinary Tract Infection (UTI) Medications Market Opportunities & Trends in Global Market
Table 2. Urinary Tract Infection (UTI) Medications Market Drivers in Global Market
Table 3. Urinary Tract Infection (UTI) Medications Market Restraints in Global Market
Table 4. Key Players of Urinary Tract Infection (UTI) Medications in Global Market
Table 5. Top Urinary Tract Infection (UTI) Medications Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Urinary Tract Infection (UTI) Medications Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Urinary Tract Infection (UTI) Medications Revenue Share by Companies, 2018-2023
Table 8. Global Companies Urinary Tract Infection (UTI) Medications Product Type
Table 9. List of Global Tier 1 Urinary Tract Infection (UTI) Medications Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Urinary Tract Infection (UTI) Medications Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Urinary Tract Infection (UTI) Medications Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Urinary Tract Infection (UTI) Medications Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Urinary Tract Infection (UTI) Medications Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Urinary Tract Infection (UTI) Medications Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Urinary Tract Infection (UTI) Medications Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Urinary Tract Infection (UTI) Medications Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2024-2029
Table 30. Pfizer Company Summary
Table 31. Pfizer Urinary Tract Infection (UTI) Medications Product Offerings
Table 32. Pfizer Urinary Tract Infection (UTI) Medications Revenue (US$, Mn) & (2018-2023)
Table 33. Pfizer Key News & Latest Developments
Table 34. AstraZeneca Company Summary
Table 35. AstraZeneca Urinary Tract Infection (UTI) Medications Product Offerings
Table 36. AstraZeneca Urinary Tract Infection (UTI) Medications Revenue (US$, Mn) & (2018-2023)
Table 37. AstraZeneca Key News & Latest Developments
Table 38. Novartis International Company Summary
Table 39. Novartis International Urinary Tract Infection (UTI) Medications Product Offerings
Table 40. Novartis International Urinary Tract Infection (UTI) Medications Revenue (US$, Mn) & (2018-2023)
Table 41. Novartis International Key News & Latest Developments
Table 42. Johnson & Johnson Company Summary
Table 43. Johnson & Johnson Urinary Tract Infection (UTI) Medications Product Offerings
Table 44. Johnson & Johnson Urinary Tract Infection (UTI) Medications Revenue (US$, Mn) & (2018-2023)
Table 45. Johnson & Johnson Key News & Latest Developments
Table 46. Roche Holding AG Company Summary
Table 47. Roche Holding AG Urinary Tract Infection (UTI) Medications Product Offerings
Table 48. Roche Holding AG Urinary Tract Infection (UTI) Medications Revenue (US$, Mn) & (2018-2023)
Table 49. Roche Holding AG Key News & Latest Developments
Table 50. Teva Pharmaceutical lndustries Company Summary
Table 51. Teva Pharmaceutical lndustries Urinary Tract Infection (UTI) Medications Product Offerings
Table 52. Teva Pharmaceutical lndustries Urinary Tract Infection (UTI) Medications Revenue (US$, Mn) & (2018-2023)
Table 53. Teva Pharmaceutical lndustries Key News & Latest Developments
Table 54. Boehringer Ingelheim Company Summary
Table 55. Boehringer Ingelheim Urinary Tract Infection (UTI) Medications Product Offerings
Table 56. Boehringer Ingelheim Urinary Tract Infection (UTI) Medications Revenue (US$, Mn) & (2018-2023)
Table 57. Boehringer Ingelheim Key News & Latest Developments
Table 58. Cipla Company Summary
Table 59. Cipla Urinary Tract Infection (UTI) Medications Product Offerings
Table 60. Cipla Urinary Tract Infection (UTI) Medications Revenue (US$, Mn) & (2018-2023)
Table 61. Cipla Key News & Latest Developments
Table 62. AdvaCare Pharma Company Summary
Table 63. AdvaCare Pharma Urinary Tract Infection (UTI) Medications Product Offerings
Table 64. AdvaCare Pharma Urinary Tract Infection (UTI) Medications Revenue (US$, Mn) & (2018-2023)
Table 65. AdvaCare Pharma Key News & Latest Developments
Table 66. Baiyunshan Pharma Company Summary
Table 67. Baiyunshan Pharma Urinary Tract Infection (UTI) Medications Product Offerings
Table 68. Baiyunshan Pharma Urinary Tract Infection (UTI) Medications Revenue (US$, Mn) & (2018-2023)
Table 69. Baiyunshan Pharma Key News & Latest Developments
Table 70. Harbin Pharmaceutical Group Company Summary
Table 71. Harbin Pharmaceutical Group Urinary Tract Infection (UTI) Medications Product Offerings
Table 72. Harbin Pharmaceutical Group Urinary Tract Infection (UTI) Medications Revenue (US$, Mn) & (2018-2023)
Table 73. Harbin Pharmaceutical Group Key News & Latest Developments
Table 74. Aurobindo Pharma Company Summary
Table 75. Aurobindo Pharma Urinary Tract Infection (UTI) Medications Product Offerings
Table 76. Aurobindo Pharma Urinary Tract Infection (UTI) Medications Revenue (US$, Mn) & (2018-2023)
Table 77. Aurobindo Pharma Key News & Latest Developments
Table 78. Alkem Laboratories Company Summary
Table 79. Alkem Laboratories Urinary Tract Infection (UTI) Medications Product Offerings
Table 80. Alkem Laboratories Urinary Tract Infection (UTI) Medications Revenue (US$, Mn) & (2018-2023)
Table 81. Alkem Laboratories Key News & Latest Developments
Table 82. Ascend Laboratories Company Summary
Table 83. Ascend Laboratories Urinary Tract Infection (UTI) Medications Product Offerings
Table 84. Ascend Laboratories Urinary Tract Infection (UTI) Medications Revenue (US$, Mn) & (2018-2023)
Table 85. Ascend Laboratories Key News & Latest Developments
List of Figures
Figure 1. Urinary Tract Infection (UTI) Medications Segment by Type in 2022
Figure 2. Urinary Tract Infection (UTI) Medications Segment by Application in 2022
Figure 3. Global Urinary Tract Infection (UTI) Medications Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Urinary Tract Infection (UTI) Medications Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Urinary Tract Infection (UTI) Medications Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Urinary Tract Infection (UTI) Medications Revenue in 2022
Figure 8. By Type - Global Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
Figure 9. By Application - Global Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
Figure 10. By Type - Global Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
Figure 12. By Application - Global Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
Figure 14. By Region - Global Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
Figure 15. By Country - North America Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
Figure 16. US Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
Figure 20. Germany Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 21. France Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
Figure 28. China Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 32. India Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
Figure 34. Brazil Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
Figure 37. Turkey Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Urinary Tract Infection (UTI) Medications Revenue, (US$, Mn), 2018-2029
Figure 41. Pfizer Urinary Tract Infection (UTI) Medications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. AstraZeneca Urinary Tract Infection (UTI) Medications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Novartis International Urinary Tract Infection (UTI) Medications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Johnson & Johnson Urinary Tract Infection (UTI) Medications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Roche Holding AG Urinary Tract Infection (UTI) Medications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Teva Pharmaceutical lndustries Urinary Tract Infection (UTI) Medications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Boehringer Ingelheim Urinary Tract Infection (UTI) Medications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Cipla Urinary Tract Infection (UTI) Medications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. AdvaCare Pharma Urinary Tract Infection (UTI) Medications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Baiyunshan Pharma Urinary Tract Infection (UTI) Medications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Harbin Pharmaceutical Group Urinary Tract Infection (UTI) Medications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Aurobindo Pharma Urinary Tract Infection (UTI) Medications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Alkem Laboratories Urinary Tract Infection (UTI) Medications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Ascend Laboratories Urinary Tract Infection (UTI) Medications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



★調査レポート[世界の尿路感染症（UTI）治療薬市場予測2023-2029：ジェネリック医薬品、先発医薬品] (コード：MMG23FB2229)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の尿路感染症（UTI）治療薬市場予測2023-2029：ジェネリック医薬品、先発医薬品]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のパクリタキセル注射（アルブミン結合）市場予測2023-2029：先発医薬品、ジェネリック医薬品
  • カームスチン注射液の世界市場2023-2029：先発医薬品、ジェネリック医薬品
  • 世界の尿路感染症（UTI）治療市場2022-2029：薬剤別（ペニシリン＆併用薬、キノロン、セファロスポリン、アゾール＆アムホテリシンB、ニトロフラン、その他）、疾患別、地域別
  • 世界の先天性高インスリン症（HI）治療薬市場予測2023-2029：ジアゾキシド、オクトレオチド、グルカゴン、その他
  • 世界の咳喘息（CVA）治療薬市場予測2023-2029：気管支拡張剤、ロイコトリエン拮抗剤、肥満細胞安定剤、コルチコステロイド、モノクローナル抗体

    • ◆H&Iグローバルリサーチのお客様（例）◆